BioVaxys 1Q2026 R&D and Collaborative Activity
Executive Summary
- BioVaxys announced participation in a BARDA Request for Information (RFI) for new vaccine platforms, positioning its DPX technology for future government contracts.
- The company disclosed ongoing high‑level discussions with a UN‑chartered organization (~US$120 M research budget) for vaccine development collaborations covering multiple pathogens.
- Positive Phase 1 clinical data were reported for MVP‑S (neoadjuvant hormone therapy in HR+/HER2‑ breast cancer) and DPX‑SurMAGE/MVP‑S vaccines in non‑muscle invasive bladder cancer, showing safety and robust antigen‑specific T‑cell responses with durable remission in many patients.
Key Details
- BARDA RFI Participation: BioVaxys is responding to BARDA’s solicitation for “New Vaccine Platforms,” a precursor to an upcoming Request for Proposal (RFP). Involvement at the RFI stage could influence selection for future government‑funded vaccine development programs.
- UN‑Chartered Organization Collaboration Talks: Through board introductions, BioVaxys is in early discussions with an international health organization that manages a ~US$120 M vaccine research budget targeting Shigella, Hepatitis B, Influenza, RSV, Rotavirus, Zika, HPV, and others. The DPX platform’s attributes (single‑dose, shelf stability, micro‑dosing) are highlighted as attractive for these programs.
- Animal Health Partner – mRNA Rabies Vaccine: Ongoing collaboration to develop a DPX‑mRNA formulation for rabies; study design under review with protocol expected to be finalized and announced shortly. The platform is claimed to enhance mRNA stability and target antigen‑presenting cells.
- Phase 1 Clinical Results – MVP‑S (Breast Cancer): Positive safety profile and significant systemic antigen‑specific T‑cell responses when combined with neoadjuvant hormone therapy in HR+/HER2‑ stage II‑III breast cancer patients.
- Phase 1 Clinical Results – DPX‑SurMAGE & MVP‑S (Bladder Cancer): In patients with recurrent high‑grade NMIBC, both vaccines were well tolerated and induced strong T‑cell responses; many patients remained recurrence‑free after ~2 years follow‑up.
- Upcoming Phase 1B/2 Study: BioVaxys is reviewing data from an additional Phase 1B/2 trial of MVP‑S in a new formulation combination, with results expected in the coming weeks.
Notable Quotes
“Attributes of our DPX platform that are attractive to their vaccine development efforts include features such as duration of immune‑activity, single‑dose non‑systemic delivery, shelf stability, and micro‑dosing capabilities.” – Kenneth Kovan, President & COO
“Since early January, we are jointly reviewing the study design and timelines for a DPX‑mRNA rabies vaccine program… Gaining additional preclinical data … we expect it to open new partnering discussions in the human mRNA vaccine space.” – Kenneth Kovan, President & COO
Materiality Assessment: Material – Positive (the release conveys substantive progress on government RFI participation, high‑value partnership talks, and favorable early clinical outcomes that could materially affect BioVaxys’ future revenue streams and valuation).